Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular disease
Pharma
Experts paint tough path ahead of Alnylam's key ATTR-CM readout
Pfizer's tafamidis is expected to maintain the lion’s share of the ATTR-CM market even if Alnylam’s HELIOS-B trial were to be positive, two KOLs said.
Angus Liu
Apr 22, 2024 10:55am
Novo Nordisk touts Wegovy's value for heart disease patients
Nov 13, 2023 10:31am
Lilly teams with Redwire on orbital drug development experiments
Oct 30, 2023 2:39pm
J&J dumps Opsumit trial upon pulmonary hypertension flop
Sep 7, 2023 11:03am
FDA approves Agepha’s version of colchicine for heart disease
Jun 20, 2023 8:10am
Jazz backs AHA to bang the drum about sleep-heart disease link
Apr 3, 2023 7:15am